GlaxoSmithKline Pharmaceuticals Limited has officially confirmed the resignation of Mr. Juby Chandy from his roles as Whole-Time Director and Chief Financial Officer (CFO). The resignation is effective from the close of business hours on March 11, 2026. This move follows Mr. Chandy’s internal appointment as the Finance Head for the Asia Pacific region at the global GSK entity. The company has informed the exchanges regarding the regulatory disclosure concerning this executive transition.
Executive Transition Confirmed
GlaxoSmithKline Pharmaceuticals Limited has formally announced a significant change in its senior management structure. In compliance with listing regulations, the company has disclosed the resignation of Mr. Juby Chandy, who held the dual positions of Whole-Time Director and Chief Financial Officer (CFO).
Effective Date and New Role
The resignation was made effective starting from the close of business hours on March 11, 2026. The departure from the Indian entity is directly linked to Mr. Chandy’s new responsibilities within the larger global organization. He has been appointed as the Finance Head for the Asia Pacific region at GSK, a move that reflects his continued association with the group in an elevated capacity.
Board Acknowledgment
In his letter dated 2nd March 2026, Mr. Chandy expressed his sincere gratitude to the Board of Directors and the Managing Director for their support during his tenure. The company acknowledged this transition, following up on the initial announcement made on March 2, 2026, by submitting the formal resignation letter to the stock exchanges on March 16, 2026.
Source: BSE
